FDA Reviews Infant RSV Treatments Amid Skeptic Concerns and Kennedy Influence
The FDA is reviewing approved infant RSV treatments, like Beyfortus, due to vaccine skeptic concerns and an investigation led by Kennedy-appointed officials, despite strong safety data.
Overview
The FDA is currently reviewing the safety of approved RSV treatments for infants, including those from Merck, Sanofi, and AstraZeneca, prompted by concerns from vaccine skeptics.
FDA officials appointed under Kennedy initiated an investigation into RSV therapies over the summer, as per Reuters, despite no reported safety issues with the approved treatments.
Sanofi confirms Beyfortus' safety and effectiveness in over 50 studies with 400,000 infants, demonstrating its significant role in reducing RSV hospitalizations.
RSV poses severe, life-threatening risks like pneumonia in high-risk infants, with 2-3% under six months hospitalized annually, emphasizing the critical need for these approved treatments.
The CDC includes these RSV therapies in its recommended childhood immunization schedule, underscoring their public health importance amidst the FDA's review influenced by Kennedy-appointed officials.
Analysis
Center-leaning sources frame the FDA's safety review of RSV drugs as politically motivated, driven by Health Secretary Robert F. Kennedy Jr.'s broader "scrutiny" of immunizations. They emphasize the lack of reported safety issues and include expert opinions suggesting the review aims to "sow distrust" and "dismantle" immunization infrastructure, rather than presenting it as a routine regulatory process.